Expression of P450 and nuclear receptors in normal and end-stage Chinese livers

World Journal of Gastroenterology

Volumn , Issue 26, 2014, Pages 8681-8690

  Chen, Hong ^a   Shen, Zhong Yang ^a   Xu, Wang ^a   Fan, Tie Yan ^a   Li, Jun ^a   Lu, Yuan Fu ^b   Cheng, Ming Liang ^c   Liu, Jie ^b  

^a GENERAL HOSPITAL OF CHINESE PEOPLE'S ARMED POLICE FORCES   (China)

^b ZUNYI MEDICAL UNIVERSITY   (China)

^c GUIZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Chinese donor livers; Cytochrome P450; End stage livers; Hepatocellular carcinoma; mRNA expression; Nuclear receptors

Indexed keywords

AROMATIC HYDROCARBON RECEPTOR; CELL NUCLEUS RECEPTOR; CONSTITUTIVE ANDROSTANE RECEPTOR; CYTOCHROME P450; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; CYTOCHROME P450 3A7; CYTOCHROME P450 4A11; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PREGNANE X RECEPTOR; CELL RECEPTOR; ISOENZYME; CYTOCHROME P450 1A2;

ADULT; AGED; ALCOHOL LIVER CIRRHOSIS; ARTICLE; CONTROLLED STUDY; END STAGE LIVER DISEASE; FEMALE; GENE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NUCLEOTIDE SEQUENCE; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; VERY ELDERLY; YOUNG ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; CASE CONTROL STUDY; CHINA; ENZYMOLOGY; EPIDEMIOLOGY; ETHNOLOGY; GENETICS; HEPATITIS B; LIVER; LIVER TUMOR; VIROLOGY; CHINESE; COMPARATIVE STUDY; HEPATITIS B VIRUS; LIVER TRANSPLANTATION; MULTIGENE FAMILY; ORGAN DONOR;

ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; CHINA; CYTOCHROME P-450 ENZYME SYSTEM; END STAGE LIVER DISEASE; HEPATITIS B; HUMANS; ISOENZYMES; LIVER; LIVER CIRRHOSIS; LIVER CIRRHOSIS, ALCOHOLIC; LIVER NEOPLASMS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RNA, MESSENGER;

EID: 84904382729     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i26.8681     Document Type: Article

References (38)

1. Parkinson A, Ogilvie BW. Biotransformation of xenobiotics. In: Klaassen CD. Casarett and Doull's Toxicology: The Basic Science of Poisons. Sydney: McGraw Hill, 2013: 185-366
2. Gonzalez FJ. The 2006 Bernard B. Brodie Award Lecture. Cyp2e1. Drug Metab Dispos 2007; 35: 1-8 [PMID: 17020953] (Pubitemid 46036469)
3. Wang H, Tompkins LM. CYP2B6: new insights into a historically overlooked cytochrome P450 isozyme. Curr Drug Metab 2008; 9: 598-610 [PMID: 18781911]
4. Johansson I, Ingelman-Sundberg M. Genetic polymorphism and toxicology - with emphasis on cytochrome p450. Toxicol Sci 2011; 120: 1-13 [PMID: 21149643 DOI: 10.1093/toxsci/kfq374]
5. Xu BY, Guo LP, Lee SS, Dong QM, Tan Y, Yao H, Li LH, Lin CK, Kung HF, He ML. Genetic variability of CYP2B6 polymorphisms in four southern Chinese populations. World J Gastroenterol 2007; 13: 2100-2103 [PMID: 17465455] (Pubitemid 46795849)
6. Neafsey P, Ginsberg G, Hattis D, Sonawane B. Genetic polymorphism in cytochrome P450 2D6 (CYP2D6): Population distribution of CYP2D6 activity. J Toxicol Environ Health B Crit Rev 2009; 12: 334-361 [PMID: 20183526 DOI: 10.1080/10937400903158342]
7. Waxman DJ, Holloway MG. Sex differences in the expression of hepatic drug metabolizing enzymes. Mol Pharmacol 2009; 76: 215-228 [PMID: 19483103 DOI: 10.1124/mol.109.056705]
8. Hines RN. Ontogeny of human hepatic cytochromes P450. J Biochem Mol Toxicol 2007; 21: 169-175 [PMID: 17936930] (Pubitemid 350194376)
9. Guengerich FP. Cytochrome p450 and chemical toxicology. Chem Res Toxicol 2008; 21: 70-83 [PMID: 18052394] (Pubitemid 351219709)
10. Kurzawski M, Dziedziejko V, Post M, Wójcicki M, Urasińska E, Mie¸tkiewski J, Droździk M. Expression of genes involved in xenobiotic metabolism and transport in end-stage liver disease: up-regulation of ABCC4 and CYP1B1. Pharmacol Rep 2012; 64: 927-939 [PMID: 23087145]
11. Gómez-Lechón MJ, Jover R, Donato MT. Cytochrome p450 and steatosis. Curr Drug Metab 2009; 10: 692-699 [PMID: 19702532]
12. Hanada K, Nakai K, Tanaka H, Suzuki F, Kumada H, Ohno Y, Ozawa S, Ogata H. Effect of nuclear receptor downregulation on hepatic expression of cytochrome P450 and transporters in chronic hepatitis C in association with fibrosis development. Drug Metab Pharmacokinet 2012; 27: 301-306 [PMID: 22166890]
13. Theile D, Haefeli WE, Seitz HK, Millonig G, Weiss J, Mueller S. Association of liver stiffness with hepatic expression of pharmacokinetically important genes in alcoholic liver disease. Alcohol Clin Exp Res 2013; 37 Suppl 1: E17-E22 [PMID: 22827451 DOI: 10.1111/j.1530-0277.2012.01901.x]
14. Fisher CD, Lickteig AJ, Augustine LM, Ranger-Moore J, Jackson JP, Ferguson SS, Cherrington NJ. Hepatic cytochrome P450 enzyme alterations in humans with progressive stages of nonalcoholic fatty liver disease. Drug Metab Dispos 2009; 37: 2087-2094 [PMID: 19651758 DOI: 10.1124/dmd.109.027466]
15. Haas S, Merkelbach-Bruse S, Justenhoven C, Brauch H, Fischer HP. Expression of xenobiotic and steroid hormone metabolizing enzymes in hepatocellular tumors of the noncirrhotic liver. Pathol Res Pract 2009; 205: 716-725 [PMID: 19596526 DOI: 10.1016/j.prp.2009.06.003]
16. Elbekai RH, Korashy HM, El-Kadi AO. The effect of liver cirrhosis on the regulation and expression of drug metabolizing enzymes. Curr Drug Metab 2004; 5: 157-167 [PMID: 15078193] (Pubitemid 38515245)
17. Schmidt A, Braeuning A, Ruck P, Seitz G, Armeanu-Ebinger S, Fuchs J, Warmann SW, Schwarz M. Differential expression of glutamine synthetase and cytochrome P450 isoforms in human hepatoblastoma. Toxicology 2011; 281: 7-14 [PMID: 21237236 DOI: 10.1016/j.tox.2011.01.006]
18. Wang YX, Meng XW, Wang YD, Liu Y. MRNA levels of two different enzymes in hepatocellular carcinoma. Hepatogastroenterology 2010; 57: 1187-1190 [PMID: 21410056]
19. Tanaka S, Mogushi K, Yasen M, Ban D, Noguchi N, Irie T, Kudo A, Nakamura N, Tanaka H, Yamamoto M, Kokudo N, Takayama T, Kawasaki S, Sakamoto M, Arii S. Oxidative stress pathways in noncancerous human liver tissue to predict hepatocellular carcinoma recurrence: a prospective, multicenter study. Hepatology 2011; 54: 1273-1281 [PMID: 22006857 DOI: 10.1002/hep.24536]
20. Waxman DJ. P450 gene induction by structurally diverse xenochemicals: central role of nuclear receptors CAR, PXR, and PPAR. Arch Biochem Biophys 1999; 369: 11-23 [PMID: 10462436] (Pubitemid 29434534)
21. Aleksunes LM, Klaassen CD. Coordinated regulation of hepatic phase I and II drug-metabolizing genes and transporters using AhR-, CAR-, PXR-, PPARá-, and Nrf2-null mice. Drug Metab Dispos 2012; 40: 1366-1379 [PMID: 22496397 DOI: 10.1124/dmd.112.045112]
22. Koutsounas I, Theocharis S, Patsouris E, Giaginis C. Pregnane X receptor (PXR) at the crossroads of human metabolism and disease. Curr Drug Metab 2013; 14: 341-350 [PMID: 23237007]
23. George J, Murray M, Byth K, Farrell GC. Differential alterations of cytochrome P450 proteins in livers from patients with severe chronic liver disease. Hepatology 1995; 21: 120-128 [PMID: 7806144]
24. Jokinen MJ, Neuvonen PJ, Lindgren L, Höckerstedt K, Sjövall J, Breuer O, Askemark Y, Ahonen J, Olkkola KT. Pharmacokinetics of ropivacaine in patients with chronic endstage liver disease. Anesthesiology 2007; 106: 43-55 [PMID: 17197844] (Pubitemid 46035402)
25. De Bock L, Boussery K, Van Winckel M, De Paepe P, Rogiers X, Stephenne X, Sokal E, Van Bocxlaer J. In vitro cytochrome p450 activity decreases in children with high pediatric end-stage liver disease scores. Drug Metab Dispos 2013; 41: 390-397 [PMID: 23150427 DOI: 10.1124/dmd.112.048504]
26. Bentué-Ferrer D, Tribut O, Verdier MC. [Therapeutic drug monitoring of lacosamide]. Therapie 2012; 67: 151-155 [PMID: 22850102]
27. Lee JB, Lee KA, Lee KY. Cytochrome P450 2C19 polymorphism is associated with reduced clopidogrel response in cerebrovascular disease. Yonsei Med J 2011; 52: 734-738 [PMID: 21786436 DOI: 10.3349/ymj.2011.52.5.734]
28. Aubert J, Begriche K, Knockaert L, Robin MA, Fromenty B. Increased expression of cytochrome P450 2E1 in nonalcoholic fatty liver disease: mechanisms and pathophysiological role. Clin Res Hepatol Gastroenterol 2011; 35: 630-637 [PMID: 21664213 DOI: 10.1016/j.clinre.2011.04.015]
29. Chiu KW, Nakano T, Hu TH, Tseng HP, Cheng YF, Jawan B, Eng HL, Goto S, Chen CL. Influence of CYP2C19 genotypes on graft pathological findings and postoperative liver function in recipients after living-donor liver transplantation. Ann Transplant 2010; 15: 38-43 [PMID: 21183874 DOI: 10.1111/j.1365-2362.2011.02589.x]
30. Klein K, Zanger UM. Pharmacogenomics of Cytochrome P450 3A4: Recent Progress Toward the "Missing Heritability" Problem. Front Genet 2013; 4: 12 [PMID: 23444277 DOI: 10.3389/fgene.2013.00012]
31. MacPhee IA. Pharmacogenetic biomarkers: cytochrome P450 3A5. Clin Chim Acta 2012; 413: 1312-1317 [PMID: 22037511 DOI: 10.1016/j.cca.2011.10.013]
32. Goldwasser J, Cohen PY, Yang E, Balaguer P, Yarmush ML, Nahmias Y. Transcriptional regulation of human and rat hepatic lipid metabolism by the grapefruit flavonoid naringenin: role of PPARalpha, PPARgamma and LXRalpha. PLoS One 2010; 5: e12399 [PMID: 20811644]
33. Parkinson A, Mudra DR, Johnson C, Dwyer A, Carroll KM. The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes. Toxicol Appl Pharmacol 2004; 199: 193-209 [PMID: 15364537 DOI: 10.1371/journal.pone.0012399] (Pubitemid 39208721)
34. Johnson TN, Boussery K, Rowland-Yeo K, Tucker GT, Rostami-Hodjegan A. A semi-mechanistic model to predict the effects of liver cirrhosis on drug clearance. Clin Pharmacokinet 2010; 49: 189-206 [PMID: 20170207 DOI: 10.2165/11318160-000000000-00000]
35. Orlando R, Padrini R, Perazzi M, De Martin S, Piccoli P, Palatini P. Liver dysfunction markedly decreases the inhibition of cytochrome P450 1A2-mediated theophylline metabolism by fluvoxamine. Clin Pharmacol Ther 2006; 79: 489-499 [PMID: 16678550]
36. Rieger JK, Klein K, Winter S, Zanger UM. Expression variability of absorption, distribution, metabolism, excretionrelated microRNAs in human liver: influence of nongenetic factors and association with gene expression. Drug Metab Dispos 2013; 41: 1752-1762 [PMID: 23733276 DOI: 10.1124/dmd.113.052126]
37. Buechler C, Weiss TS. Does hepatic steatosis affect drug metabolizing enzymes in the liver? Curr Drug Metab 2011; 12: 24-34 [PMID: 21222589]
38. Albarmawi A, Czock D, Gauss A, Ehehalt R, Lorenzo Bermejo J, Burhenne J, Ganten TM, Sauer P, Haefeli WE. CYP3A activity in severe liver cirrhosis correlates with Child-Pugh and model for end-stage liver disease (MELD) scores. Br J Clin Pharmacol 2014; 77: 160-169 [PMID: 23772874 DOI: 10.1111/bcp.12182]